- ISIN
- US1920051067
- CUSIP
- 192005106
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 22, 2010
Highlights
- Market Cap
- $215.12M
- Enterprise Value
- $254.75M
- EPS (TTM)
- -$0.36
- Total Revenue (TTM)
- $78.09M
- Gross Profit (TTM)
- $64.33M
- EBITDA (TTM)
- -$19.32M
- Year Range
- $0.96 - $3.87
- Target Price
- $5.00
- ROA (TTM)
- -396.41%
- ROE (TTM)
- -73.99%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CDXS Performance Chart
Codexis, Inc. (CDXS) is up 45.4% since the beginning of the year. At $2 per share, CDXS is trading 38.8% below its 52-week high of $4. Investors who bought $1,000 worth of CDXS shares 5 years ago would now be looking at an investment worth $111.
Loading charts...
Returns By Period
Codexis, Inc. (CDXS) has returned 45.40% so far this year and 3.49% over the past 12 months. Over the last ten years, CDXS has returned -5.49% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Codexis, Inc.
- 1D
- -7.78%
- 1M
- -4.82%
- YTD
- 45.40%
- 6M
- 39.41%
- 1Y
- 3.49%
- 3Y*
- -5.41%
- 5Y*
- -35.56%
- 10Y*
- -5.49%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
CDXS Monthly Returns History
Based on dividend-adjusted daily data since Apr 22, 2010, CDXS's average daily return is +0.05%, while the average monthly return is +0.95%. At this rate, an investment would double in approximately 6.1 years.
Historically, 47% of months were positive and 53% were negative. The best month was Feb 2024 with a return of +76.8%, while the worst month was Aug 2023 at -51.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, CDXS closed higher 47% of trading days. The best single day was Jul 15, 2014 with a return of +44.0%, while the worst single day was Jul 15, 2022 at -44.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -23.93% | -18.55% | 61.39% | 73.01% | -1.77% | -14.44% | 45.40% | ||||||
| 2025 | -12.16% | -27.45% | -11.51% | -14.50% | -0.00% | 6.09% | 9.84% | 1.87% | -10.62% | -2.87% | -27.00% | -5.78% | -65.83% |
| 2024 | -13.77% | 76.81% | -24.95% | -16.62% | 16.15% | -8.28% | 15.48% | -19.27% | 6.57% | 1.95% | 45.86% | 4.15% | 56.39% |
| 2023 | 31.97% | -21.38% | -14.37% | -5.31% | -43.62% | 26.70% | 28.57% | -51.67% | 8.62% | -12.17% | 42.17% | 29.24% | -34.55% |
| 2022 | -34.44% | -2.78% | 3.46% | -41.66% | -11.22% | -2.06% | -34.42% | 2.19% | -13.55% | -7.26% | -2.67% | -14.81% | -85.10% |
| 2021 | 6.69% | -5.07% | 3.53% | 1.27% | -11.56% | 10.54% | -6.62% | 27.69% | -13.92% | 49.48% | -0.17% | -9.91% | 43.24% |
Benchmark Metrics
Codexis, Inc. has an annualized alpha of -5.08%, beta of 1.41, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since April 22, 2010.
- This stock participated in 153.08% of S&P 500 Index downside but only 54.65% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -5.08%
- Beta
- 1.41
- R²
- 0.13
- Upside Capture
- 54.65%
- Downside Capture
- 153.08%
Return for Risk
Risk / Return Rank
CDXS ranks 45 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Codexis, Inc. (CDXS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CDXS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.99 | ||
| Sortino ratioReturn per unit of downside risk | -2.04 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.37 | -0.29 |
| Calmar ratioReturn relative to maximum drawdown | 0.05 | 2.78 | -2.73 |
| Martin ratioReturn relative to average drawdown | 0.09 | 12.44 | -12.35 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Codexis, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Codexis, Inc. was 97.65%, occurring on Mar 3, 2026. The portfolio has not yet recovered.
The current Codexis, Inc. drawdown is 94.33%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -97.65%Mar 2026 | 4y 3mo | — | 4y 7moNov 2021 - now |
2013 bear market2013 | -91.35%Dec 2013 | 3y 8mo | 4y 5mo | 8y 1moApr 2010 - May 2018 |
COVID crash2020 | -61.10%Mar 2020 | 1y 3mo | 9mo 11d | 2y 19dDec 2018 - Dec 2020 |
2021 bear market2021 | -39.31%May 2021 | 3mo | 5mo | 8moFeb 2021 - Oct 2021 |
Rate-hike selloffLate 2018 | -26.39%Oct 2018 | 28d | 1mo 5d | 2mo 3dSep 2018 - Nov 2018 |
Drawdown Indicators
| CDXS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.65% | -56.78% | -40.87% |
Max Drawdown (1Y)Largest decline over 1 year | -70.57% | -9.10% | -61.47% |
Max Drawdown (3Y)Largest decline over 3 years | -83.13% | -18.90% | -64.23% |
Max Drawdown (5Y)Largest decline over 5 years | -97.65% | -25.43% | -72.22% |
Max Drawdown (10Y)Largest decline over 10 years | -97.65% | -33.92% | -63.73% |
Current DrawdownCurrent decline from peak | -94.33% | -1.80% | -92.53% |
Average DrawdownAverage peak-to-trough decline | -62.62% | -10.71% | -51.91% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 38.21% | 2.03% | +36.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Codexis, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Codexis, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CDXS relative to other companies in the Biotechnology industry. Currently, CDXS has a P/S ratio of 2.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CDXS in comparison with other companies in the Biotechnology industry. Currently, CDXS has a P/B value of 5.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CDXS
Add Codexis, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CDXS